Odonate (Odonate) Cash, Cash Equivalents, Marketable Securities : $95.03 Mil (As of Sep. 2021)

View and export this data going back to 2017. Start your Free Trial

What is Odonate Cash, Cash Equivalents, Marketable Securities?

Odonate's quarterly cash, cash equivalents, marketable securities declined from Mar. 2021 ($133.16 Mil) to Jun. 2021 ($110.13 Mil) but then stayed the same from Jun. 2021 ($110.13 Mil) to Sep. 2021 ($95.03 Mil).

Odonate's annual cash, cash equivalents, marketable securities increased from Dec. 2018 ($139.05 Mil) to Dec. 2019 ($180.46 Mil) but then declined from Dec. 2019 ($180.46 Mil) to Dec. 2020 ($157.27 Mil).

Odonate Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Odonate's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Odonate Cash, Cash Equivalents, Marketable Securities Chart

Odonate Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

2.60

198.11

139.05

180.46

157.27

Odonate Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															188.26	157.27	133.16	110.13	95.03

Odonate Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Odonate (OTCPK:ODTCD) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Odonate Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Odonate's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Odonate (Odonate) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Odonate Inc (OTCPK:ODTCD) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

3 East 28th Street, 10th Floor, New York, NY, USA, 10016

Website

https://www.odonate.com

Odonate Inc is a Shell company.

Executives

Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Boxer Capital, Llc	director, 10 percent owner	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Kevin C Tang	director, 10 percent owner, officer: Chief Executive Officer	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Aaron I. Davis	director, 10 percent owner	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Craig A Johnson	director	C/O PURE BIOSCIENCE, 1725 GILLESPIE WAY, EL CAJON CA 92020
Jeff L Vacirca	director	4747 EXECUTIVE DRIVE, SUITE 510, SAN DIEGO CA 92121
Laura L. Johnson	director	C/O LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA VILLAGE DRIVE, SUITE 1070, SAN DIEGO CA 92122
Michael S Hearne	officer: Chief Financial Officer	4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121
Joseph P O'connell	officer: Chief Medical Officer	4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121
Boxer Asset Management Inc.	10 percent owner	CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Robert Rosen	director	C/O HERON THERAPEUTICS, INC, 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO CA 92121
Joseph Lewis	10 percent owner	PO BOX N7776, LYFORD BAHAMAS
Tang Capital Management Llc	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
John G Lemkey	officer: Chief Financial Officer	4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121